retatrutide parkinson's disease clinical trial Thinking about joining a but not sure where to start? Research participation is personal, and the “right” trial looks different for everyone. It's important to understand what 🎙️ NEW EPISODE: Retatrutide—The Triple

L.GmezH.KellumJ

30.3% at 104 weeks in a BMI 35 extension cohort TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First completed diabetes-specific Phase 3 trial -2.0% HbA1c and 16.8% weight loss in 537 patients, a separate program from TRIUMPH NDA timeline unchanged: industry estimates continue to expect Q4 2026 filing, based on standard practice following TRIUMPH-1's primary readout Timeline unchanged: FDA approval late 2027, market launch Q1Q2 2028 OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour This page updates after every trial announcement bookmark for the latest Introduction Retatrutide stands at the forefront of obesity medicine a first-in-class triple hormone agonist that has demonstrated some of the highest weight loss efficacy ever recorded in clinical trials

Research-grade Cagrilintide is typically supplied with purity of 98% verified by RP-HPLC

It requires guidance from a qualified healthcare provider who understands metabolic health, hormone changes across the lifespan, and how GLP-1 medications work

HRT patients managing injectable estradiol or progesterone at home

Furthermore, participants who remained consistent on the treatment lost 20% or more of their body weight